TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL

Results from the phase III TRIANGLE study showed improved failure-free survival and acceptable safety with the addition of ibrutinib to standard CIT with or without ASCT in patients 65 years of age or younger with previously untreated MCL.